Targeting fatty acid amide hydrolase as a therapeutic strategy for antitussive therapy
暂无分享,去创建一个
M. Belvisi | G. McMurray | S. Bonvini | M. Birrell | E. Dubuis | M. Papakosta | R. Kinloch | Sarah A. Maher | S. Maher | C. Perros-Huguet | J. Adcock | M. Wortley | I. Delescluse | Christelle Perros-Huguet
[1] R. Carnuccio,et al. Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis. , 2016, European journal of pharmacology.
[2] Xin Jin,et al. N-Oleoylethanolamine Reduces Inflammatory Cytokines and Adhesion Molecules in TNF-&agr;-induced Human Umbilical Vein Endothelial Cells by Activating CB2 and PPAR-&agr; , 2016, Journal of cardiovascular pharmacology.
[3] M. Shabani,et al. Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors , 2015, Epilepsy Research.
[4] Gary Layton,et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study , 2015, The Lancet.
[5] J. Smith,et al. Targeting TRP channels for chronic cough: from bench to bedside , 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.
[6] J. Smith,et al. Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial. , 2014, The Journal of allergy and clinical immunology.
[7] M. Belvisi,et al. Theophylline inhibits the cough reflex through a novel mechanism of action☆ , 2014, The Journal of allergy and clinical immunology.
[8] M. Belvisi,et al. Harvesting, Isolation, and Functional Assessment of Primary Vagal Ganglia Cells , 2013, Current protocols in pharmacology.
[9] C. Hiley,et al. Mechanisms of vasorelaxation induced by oleoylethanolamide in the rat small mesenteric artery. , 2013, European journal of pharmacology.
[10] G. Jay,et al. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. , 2012, British journal of clinical pharmacology.
[11] M. Meyers. Discovery of Novel Spirocyclic Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Part 2. Discovery of 7‐Azaspiro[3.5]nonane Urea PF‐04862853 (I), an orally Efficacious Inhibitor of Fatty Acid Amide Hydrolase (FAAH) for Pain. , 2012 .
[12] M. C. Walker,et al. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain. , 2011, Bioorganic & medicinal chemistry letters.
[13] L. Devi,et al. The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic Implications , 2011, Pharmacological Reviews.
[14] Stephen P. H. Alexander,et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.
[15] I. Cuthill,et al. Reporting : The ARRIVE Guidelines for Reporting Animal Research , 2010 .
[16] I. Khanna,et al. Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases. , 2009, Drug discovery today.
[17] B. Cravatt,et al. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders , 2009, Expert opinion on drug discovery.
[18] Raymond C Stevens,et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. , 2009, Chemistry & biology.
[19] A. Lichtman,et al. Targeting Fatty Acid Amide Hydrolase (FAAH) to Treat Pain and Inflammation , 2009, The AAPS Journal.
[20] D. Barrett,et al. ‘Entourage’ effects of N‐palmitoylethanolamide and N‐oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors , 2008, British journal of pharmacology.
[21] M. Belvisi,et al. Inhibitory activity of the novel CB2 receptor agonist, GW833972A, on guinea‐pig and human sensory nerve function in the airways , 2008, British journal of pharmacology.
[22] G. Benedek,et al. The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level , 2008, PAIN.
[23] S. O'Sullivan,et al. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors , 2007, British journal of pharmacology.
[24] Shou-Dong Lee,et al. Role of Ca2+‐dependent potassium channels in in vitro anandamide‐mediated mesenteric vasorelaxation in rats with biliary cirrhosis , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[25] V. Di Marzo,et al. Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. , 2007, Experimental cell research.
[26] B. Fakler,et al. Organization and Regulation of Small Conductance Ca2+-activated K+ Channel Multiprotein Complexes , 2007, The Journal of Neuroscience.
[27] S. Mazzone,et al. Vagal afferent nerves regulating the cough reflex , 2006, Respiratory Physiology & Neurobiology.
[28] D. Forman,et al. Cough in the community: a cross sectional survey and the relationship to gastrointestinal symptoms , 2006, Thorax.
[29] Sandy J. Wilson,et al. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms , 2006, British journal of pharmacology.
[30] Sandy J. Wilson,et al. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms , 2006 .
[31] B. Birnir,et al. Endogenous Unsaturated C18 N-Acylethanolamines Are Vanilloid Receptor (TRPV1) Agonists* , 2005, Journal of Biological Chemistry.
[32] O. Usmani,et al. Chronic idiopathic cough: a discrete clinical entity? , 2005, Chest.
[33] D. Piomelli,et al. The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.
[34] S. Gaetani,et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α , 2003, Nature.
[35] M. Yacoub,et al. Inhibition of guinea‐pig and human sensory nerve activity and the cough reflex in guinea‐pigs by cannabinoid (CB2) receptor activation , 2003, British journal of pharmacology.
[36] C. Page,et al. RSD931, a novel anti‐tussive agent acting on airway sensory nerves , 2003, British journal of pharmacology.
[37] T. Fahey,et al. Systematic review of randomised controlled trials of over the counter cough medicines for acute cough in adults , 2002, BMJ : British Medical Journal.
[38] G. Thakur,et al. Cannabinergic ligands. , 2002, Chemistry and physics of lipids.
[39] P. Casellas,et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.
[40] H. Homma,et al. Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[41] P. Soubrié,et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.